Inmune bio, inc. (INMB)
CashFlow / Yearly
Dec'19Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS

-7,678

-12,440

-831

Adjustments to reconcile net loss to net cash used in operating activities:
Net cash used in operating activities:
Stock-based compensation

4,096

10,001

199

Gain on waiver of common stock issuable

1,542

-

-

Gain on legal settlements

-

-

150

Changes in operating assets and liabilities:
Research and development tax credit receivable

-24

485

38

Other tax receivable

39

-74

76

Joint development cost receivable

17

91

47

Prepaid expenses

82

-27

39

Prepaid expenses - related party

26

-158

112

Accounts payable and accrued liabilities

-151

426

68

Accounts payable and accrued liabilities - related parties

19

87

170

Operating lease liability - related party

-23

-

-

Net cash used in operating activities

-5,384

-2,058

-761

Cash paid for acquired in-process research and development intangible assets

-

-

100

Net cash used in investing activities

-

-

-100

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock

12,209

900

2,056

Net cash (used in) provided by financing activities

12,209

900

2,056

Impact on cash from foreign currency translation

-15

-25

34

NET (DECREASE) INCREASE IN CASH

6,809

-1,184

1,229

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes

-

-

0

Cash paid for interest expense

-

-

0

NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of warrants to placement agents

247

-

-

Issuance of common stock and warrants for acquired in-process research and development intangible asset

-

-

16,414

Conversion of related party debt to common stock

-

-

350

Issuance of common stock issuable

3,084

-

30